Eisai Company, Ltd. (ESALY.PK) Submits Application To Expand Indication Of Anti-Alzheimer's Agent Aricept® As Treatment For Dementia With Lewy Bodies In Japan
12/10/2013 11:04:32 AM
Tokyo, Oct 31, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), announced today that it has filed an application for the anti-Alzheimer's agent Aricept(R) (donepezil hydrochloride, "donepezil") in Japan, requesting a new indication expansion to use the agent in the treatment of dementia with Lewy bodies (DLB).
Help employers find you! Check out all the jobs and post your resume.
comments powered by